Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

Conditions

• Follicular Helper T-Cell Lymphoma
• Peripheral T-Cell Lymphoma, Not Otherwise Specified

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Biospecimen Collection — PROCEDURE
  Undergo blood sample collection
• Bone Marrow Aspiration — PROCEDURE
  Undergo bone marrow aspiration
• Bone Marrow Biopsy — PROCEDURE
  Undergo bone marrow biopsy
• Computed Tomography — PROCEDURE
  Undergo CT scan
• Duvelisib — DRUG
  Given PO
• Positron Emission Tomography — PROCEDURE
  Undergo PET scan
• Survey Administration — OTHER
  Ancillary studies

Study Details

This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy (maintenance) for patients with peripheral T-cell lymphomas. Duvelisib is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells.

Key Dates

Start date

Jun 7, 2026

Status verified

May 2026

Primary completion

Nov 23, 2027

Completion

Nov 23, 2027

Study Design

Enrollment

25 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (duvelisib)
  Patients receive duvelisib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain in continuous complete response may continue to receive duvelisib for an additional 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and biopsy during screening, as well as PET/CT scans and blood sample collection throughout the study. Patients may also undergo bone marrow aspiration and biopsy on study.

Primary Outcome Measure

Progression free survival [ Time Frame: At 1 year ]

Locations (1)

Find similar trials in Duarte, CA

Related Studies

• A Registry for People With T-cell Lymphoma
  Recruiting · Memorial Sloan Kettering Cancer Center · Duarte, California
• Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
  PHASE3 · Recruiting · Corvus Pharmaceuticals, Inc. · Duarte, California
• Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
  PHASE3 · Recruiting · Eastern Cooperative Oncology Group · Birmingham, Alabama
• Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
  PHASE1 · Recruiting · City of Hope Medical Center · Duarte, California